APA (7th ed.) Citation

Pica, T., Hegenbart, U., Maier, B., Kimmich, C., & Schönland, S. (2018). First report of ibrutinib in IgM-related amyloidosis: Few responses, poor tolerability, and short survival. Blood, 131(3), . https://doi.org/10.1182/blood-2017-09-806463

Chicago Style (17th ed.) Citation

Pica, Tomas, Ute Hegenbart, Bettina Maier, Christoph Kimmich, and Stefan Schönland. "First Report of Ibrutinib in IgM-related Amyloidosis: Few Responses, Poor Tolerability, and Short Survival." Blood 131, no. 3 (2018). https://doi.org/10.1182/blood-2017-09-806463.

MLA (9th ed.) Citation

Pica, Tomas, et al. "First Report of Ibrutinib in IgM-related Amyloidosis: Few Responses, Poor Tolerability, and Short Survival." Blood, vol. 131, no. 3, 2018, https://doi.org/10.1182/blood-2017-09-806463.